Rosen Law Firm Advocates for Marinus Pharmaceuticals Investors to Act Before Class Action Deadline

Rosen Law Firm, renowned for championing global investor rights, is issuing a crucial reminder to Marinus Pharmaceuticals, Inc. MRNS investors concerning an upcoming deadline in the securities class action that was initiated by the firm. Those who have invested in Marinus Pharmaceuticals are urged to seek legal counsel promptly to safeguard their rights.

Urgency for Investors to Act

With the deadline rapidly approaching, Rosen Law Firm stresses the importance of investors' responsiveness if they have purchased Marinus Pharmaceuticals securities. The law firm, known for its trusted leadership in such litigations, is poised to assist investors in navigating the complexities of the class action process.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. MRNS, a clinical-stage pharmaceutical enterprise based in Radnor, Pennsylvania, concentrates its efforts on developing and commercializing medical treatments specially targeted at rare seizure disorders. The company's dedication to advancing its therapeutic research and product pipeline reflects its commitment to addressing the urgent needs of patients afflicted by these rare conditions.

Rosen, Marinus, Investors